CoChat

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

Open access
Joy, Tisha R, McKenzie, Charles A, Tirona, Rommel G, Summers, Kelly, Seney, Shannon, Chakrabarti, Subrata, Malhotra, Neel, Beaton, Melanie D · 2017 · World Journal of Gastroenterology
Cited by 152

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

AIM: placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH). METHODS: = 6) for 24 wk. The primary outcome was improvement in liver fibrosis after 24 wk. Secondary outcomes included evaluation of changes in NAFLD activity score (NAS), individual components of NAS (hepatocyte ballooning, lobular inflammation, and steatosis), glycemic control and insulin resistance [including measurements of glycated hemoglobin (HbA1C) and adipocytokines], lipid profile including free fatty acids, adipose distribution measured using magnetic resonance imaging (MRI), and thrombosis markers (platelet aggregation and plasminogen activator inhibitor 1 levels). We also sought to determine the correlation between changes in hepatic fat fraction (%) [as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation (IDEAL) MRI technique] and changes in hepatic steatosis on liver biopsy. RESULTS: = 0.002. CONCLUSION: Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy. The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v23.i1.141

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 29

  1. 10.3748/wjg.v20.i45.16841 · DOI
  2. 10.1038/nrgastro.2013.171 · DOI · Paper page
  3. 10.1002/hep.25762 · DOI · Paper page
  4. 10.1002/hep.20818 · DOI · Paper page
  5. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970;3:371-407.
  6. 10.1111/j.1365-2036.2011.04724.x · DOI · Paper page
  7. 10.1002/hep.23623 · DOI · Paper page
  8. 10.1002/hep.23270 · DOI · Paper page
  9. 10.1016/j.jhep.2010.09.032 · DOI · Paper page
  10. 10.1073/pnas.0631828100 · DOI · Paper page
  11. 10.3892/mmr.2015.4329 · DOI
  12. 10.3109/09537104.2012.721907 · DOI
  13. 10.1186/1472-6823-8-14 · DOI · Paper page
  14. Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC, Davies MJ, Wagner JA, Herman GA. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-e170.
  15. 10.5754/hge11263 · DOI · Paper page
  16. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012;75:240-244.
  17. 10.1016/j.jhep.2016.04.021 · DOI · Paper page
  18. 10.1002/mrm.20624 · DOI · Paper page
  19. 10.1002/jmri.21751 · DOI · Paper page
  20. 10.1002/jmri.21957 · DOI · Paper page
  21. 10.1148/radiol.09090131 · DOI · Paper page
  22. 10.1148/radiol.10100708 · DOI · Paper page
  23. 10.1186/1471-2342-7-3 · DOI
  24. 10.1002/jmri.22603 · DOI
  25. 10.1016/j.thromres.2006.01.019 · DOI · Paper page
  26. 10.1089/met.2012.0128 · DOI
  27. 10.1042/CS20100372 · DOI
  28. Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014;61:323-328.
  29. 10.1111/hepr.12077 · DOI

Cited by

See all 152

Metadata

Authors
Joy, T. R., McKenzie, C. A., Tirona, R. G., Summers, K., Seney, S., Chakrabarti, S., Malhotra, N., & Beaton, M. D.
Venue
World Journal of Gastroenterology
Published
2017
Volume
23
Issue
1
Pages
141
ISSN
1007-9327 (ISSN-L)
OpenAlex
W2569813586
Cited by
152
References
12
FWCI
12.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.3748/wjg.v23.i1.141
The paper
Joy, T. R., McKenzie, C. A., Tirona, R. G., Summers, K., Seney, S., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017). Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v23.i1.141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.